Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
70 hedge funds and large institutions have $146M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 14 closing their positions.
53% more capital invested
Capital invested by funds: $95.5M → $146M (+$50.7M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
33% more call options, than puts
Call options by funds: $117K | Put options by funds: $88K
11% more funds holding
Funds holding: 63 → 70 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.93M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$3.38M |
| 3 |
HCM
Highbridge Capital Management
New York
|
+$1.88M |
| 4 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$881K |
| 5 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$846K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.62M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.27M |
| 3 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$1.64M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.18M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$1.08M |
THRX Hedge Fund Activity: Q4 2023 in Review
70 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q4 2023, worth a combined $146M — up 53% from $95.5M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new THRX positions and 14 closed out — a net gain of 7 holders — while 21 added to existing stakes and 15 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $9.93M. The largest seller was Millennium Management, exiting entirely with an estimated $4.62M sold.
- 70 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q4 2023, up from 63 in Q3 2023.
- Funds reported $146M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q4 2023, up 53% quarter-over-quarter.
- 21 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q4 2023 and 14 closed out, a net change of +7 holders.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q4 2023 was Tang Capital Management, an estimated $9.93M added.
- The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q4 2023 was Millennium Management, an estimated $4.62M sold.
Based on aggregated 13F filings for Q4 2023.